Stem Cells http://www.peprotech.com/
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lok, S.
Right arrow Articles by Foster, D. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lok, S.
Right arrow Articles by Foster, D. C.

Stem Cells, Vol 12, 586-598, Copyright © 1994 by AlphaMed Press

REVIEWS

The structure, biology and potential therapeutic applications of recombinant thrombopoietin

S Lok and DC Foster
Cytokine Research Center, ZymoGenetics Corporation, Seattle, WA 98102.

Platelets, an integral component of hemostasis, are produced by megakaryocytes derived from the differentiation of pluripotent stem cells in the bone marrow or spleen. After decades of study, the regulation of this process is still not well understood. However, the recent cloning and characterization of thrombopoietin, a ligand for the receptor encoded by the c-mpl proto-oncogene, provides new insights into the humoral regulation of megakaryocytopoiesis and platelet production. Consistent with the proposed role as a major physiological regulator of megakaryocytopoiesis, thrombopoietin has potent effects on megakaryocytopoiesis in vitro and in vivo. In addition to the original supposition that thrombopoietin functions as a late-acting megakaryocyte maturation factor, recombinant thrombopoietin proves also to be a potent stimulator of hematopoietic progenitor cells, inducing them to undergo proliferation and differentiation into megakaryocytic colonies. When administered to mice, thrombopoietin causes an increase in peripheral platelet numbers to previously unattainable levels within a few days. Studies of the efficacy of thrombopoietin are underway. It is envisaged that this new cytokine will have widespread applications as a therapeutic agent for the management of bleeding due to thrombocytopenias, in particular those resulting from cancer chemo- or irradiation therapy.


This article has been cited by other articles:


Home page
 BloodHome page
M. Chang, J. X. Qian, S. m. Lee, J. Joubran, G. Fernandez, J. Nichols, A. Knoppel, and J. S. Buzby
Tissue Uptake of Circulating Thrombopoietin Is Increased in Immune-Mediated Compared With Irradiated Thrombocytopenic Mice
Blood, April 15, 1999; 93(8): 2515 - 2524.
[Abstract] [Full Text] [PDF]

Home page
 Stem CellsHome page
J. Birkmann, S. Oez, M. Smetak, G. Kaiser, H. Kappauf, and W. M. Gallmeier
Effects of Recombinant Human Thrombopoietin Alone and in Combination with Erythropoietin and Early-Acting Cytokines on Human Mobilized Purified CD34+ Progenitor Cells Cultured in Serum-Depleted Medium
Stem Cells, January 1, 1997; 15(1): 18 - 32.
[Abstract] [Full Text]

Home page
 Stem CellsHome page
R. Andrews, A Winkler, D Myerson, R. Briddell, G. Knitter, I. McNiece, and P Hunt
Recombinant human ligand for MPL, megakaryocyte growth and development factor (MGDF), stimulates thrombopoiesis in vivo in normal and myelosuppressed baboons
Stem Cells, November 1, 1996; 14(6): 661 - 677.
[Abstract]

Home page
 Stem CellsHome page
M. Ratajczak, J Ratajczak, J Ford, R Kregenow, W Marlicz, and A. Gewirtz
FLT3/FLK-2 (STK-1) Ligand does not stimulate human megakaryopoiesis in vitro
Stem Cells, January 1, 1996; 14(1): 146 - 150.
[Abstract]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
STEM CELLS THE ONCOLOGIST CME ALPHAMED PRESS JOURNALS

Copyright © 1994 by AlphaMed Press.